These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29032942)

  • 1. Aspartate aminotransferase-to-platelet ratio predicts response to transarterial chemoembolisation and prognosis in hepatocellular carcinoma patients.
    Tang T; Qiu JL; Li GW; Huang MP; Li Y; Li YJ; Gu SZ
    Clin Radiol; 2018 Mar; 73(3):259-265. PubMed ID: 29032942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection.
    Ji F; Fu S; Guo Z; Pang H; Chen D; Wang X; Ju W; Wang D; He X; Hua Y; Peng B
    Oncotarget; 2016 Nov; 7(44):72276-72289. PubMed ID: 27472390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil-to-lymphocyte and aspartate-to-alanine aminotransferase ratios predict hepatocellular carcinoma prognosis after transarterial embolization.
    Liu C; Jia BS; Zou BW; Du H; Yan LN; Yang JY; Jiang L; Wen TF; Lu WS
    Medicine (Baltimore); 2017 Nov; 96(45):e8512. PubMed ID: 29137051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspartate aminotransferase-to-platelet ratio index predicts prognosis of hepatocellular carcinoma after postoperative adjuvant transarterial chemoembolization.
    Zhu GQ; Wang K; Wang B; Zhou YJ; Yang Y; Chen EB; Zhou ZJ; Zhou SL; Shi YH; Zhou J; Dai Z
    Cancer Manag Res; 2019; 11():63-79. PubMed ID: 30588111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel and accurate predictor of survival for patients with hepatocellular carcinoma after surgical resection: the neutrophil to lymphocyte ratio (NLR) combined with the aspartate aminotransferase/platelet count ratio index (APRI).
    Ji F; Liang Y; Fu SJ; Guo ZY; Shu M; Shen SL; Li SQ; Peng BG; Liang LJ; Hua YP
    BMC Cancer; 2016 Feb; 16():137. PubMed ID: 26907597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma.
    Kim DY; Ryu HJ; Choi JY; Park JY; Lee DY; Kim BK; Kim SU; Ahn SH; Chon CY; Han KH
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1343-50. PubMed ID: 22486716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort.
    Adhoute X; Pénaranda G; Raoul JL; Pietri O; Bronowicki JP; Castellani P; Perrier H; Monnet O; Bayle O; Oules V; Pol B; Beaurain P; Muller C; Cassagneau P; Bourlière M
    Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1414-1423. PubMed ID: 31045613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of serum inflammatory markers in predicting early refractoriness of transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer Stage 0, A, and B hepatocellular carcinoma.
    Yang J; Zhang Y; Kong Y; Lin J; Zhu G; Zhang H; Yu Z; Liu P; Xia J
    Braz J Med Biol Res; 2024; 57():e13661. PubMed ID: 39258671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
    Maeda N; Osuga K; Higashihara H; Tomoda K; Mikami K; Nakazawa T; Nakamura H; Tomiyama N
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the prognostic value of platelet-based prognostic models in patients with malignant hepatic tumors after TACE therapy.
    Du QC; Hu CL; Wang YY; Zhou Y
    Acta Cir Bras; 2019 Sep; 34(7):e201900710. PubMed ID: 31531530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Noninvasive Fibrosis Markers and Postoperative Mortality After Hepatectomy for Hepatocellular Carcinoma.
    Maegawa FB; Shehorn L; Aziz H; Kettelle J; Jie T; Riall TS
    JAMA Netw Open; 2019 Jan; 2(1):e187142. PubMed ID: 30657533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with unresectable hepatocellular carcinoma beyond Milan criteria: should we perform transarterial chemoembolization or liver transplantation?
    Kim JM; Kwon CH; Joh JW; Kim SJ; Shin M; Kim EY; Moon JI; Jung GO; Choi GS; Lee SK
    Transplant Proc; 2010 Apr; 42(3):821-4. PubMed ID: 20430181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma.
    Hucke F; Pinter M; Graziadei I; Bota S; Vogel W; Müller C; Heinzl H; Waneck F; Trauner M; Peck-Radosavljevic M; Sieghart W
    J Hepatol; 2014 Dec; 61(6):1287-96. PubMed ID: 25016222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative albumin-bilirubin grade combined with aspartate aminotransferase-to-platelet count ratio index predict outcomes of patients with hepatocellular carcinoma within Milan criteria after liver resection.
    Luo H; Li C; Chen L
    Biosci Trends; 2019 May; 13(2):176-181. PubMed ID: 31061272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization.
    Guo M; Qi F; Rao Q; Sun J; Du X; Qi Z; Yang B; Xia J
    Front Immunol; 2021; 12():754961. PubMed ID: 34691076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective pilot study to examine the potential of aspartate aminotransferase to alanine aminotransferase ratio as a predictor of postoperative acute kidney injury in patients with hepatocellular carcinoma.
    Xu J; Xia Y; Li S; Cheng X; Hu S; Gao Y; Zhou X; Wang G; Zheng Q
    Ann Clin Biochem; 2019 May; 56(3):357-366. PubMed ID: 30453754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A simple, noninvasively determined index predicting hepatic failure following liver resection for hepatocellular carcinoma.
    Ichikawa T; Uenishi T; Takemura S; Oba K; Ogawa M; Kodai S; Shinkawa H; Tanaka H; Yamamoto T; Tanaka S; Yamamoto S; Hai S; Shuto T; Hirohashi K; Kubo S
    J Hepatobiliary Pancreat Surg; 2009; 16(1):42-8. PubMed ID: 19082913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection.
    Hann HW; Wan S; Lai Y; Hann RS; Myers RE; Patel F; Zhang K; Ye Z; Wang C; Yang H
    J Gastroenterol Hepatol; 2015 Jan; 30(1):131-138. PubMed ID: 24995497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative aspartate aminotransferase-to-platelet ratio index (APRI) is a predictor on postoperative outcomes of hepatocellular carcinoma.
    Cheng J; Zhao P; Liu J; Liu X; Wu X
    Medicine (Baltimore); 2016 Nov; 95(48):e5486. PubMed ID: 27902606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
    Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P
    J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.